山东新华医疗器械股份有限公司 2026 年第一次临时股东会资料 现场会议时间：2026 年 2 月 25 日（周三）上午 9:00 现场会议地点：公司办公楼三楼会议室 现场会议地址：山东省淄博市高新技术产业开发区泰美路 7 号新华医疗科技园 现场会议议程： 1、选举监票人； 二О二六年一月三十日 新华医疗 2026 年第一次临时股东会 山东新华医疗器械股份有限公司 2026 年第一次临时股东会会议议程 山东新华医疗器械股份有限公司 关于换选公司董事的议案 2、审议《关于换选公司董事的议案》； 3、对审议议题表决； 4、监票人宣布表决结果； 5、宣布股东会决议； 6、律师宣读法律意见书； 7、宣布股东会结束。 1 新华医疗 2026 年第一次临时股东会 股东会 会议资料之一 各位股东及股东代表: 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）董事李孝利 先生因工作调动已向公司董事会提交了书面辞职申请，申请辞去公司第十一届董事会 董事职务，根据《公司法》、《上海证券交易所股票上市规则》及《公司章程》等有关 规定，公司于 2026 年 1 月 30 日召开了第十一届董事会第二十五次会议，会议审议通 ...

Group 1 - The company Shandong Xinhua Medical Instrument Co., Ltd. won a bid for a procurement project from the Jilin Provincial Health Commission, with a bid amount of 1.285 million yuan [1] - In 2024, Xinhua Medical (600587.SH) reported an operating revenue of 10.021 billion yuan, with a growth rate of 0.09% [2][3] - The net profit attributable to the parent company for 2024 was 692 million yuan, reflecting a growth rate of 5.75% [2][3] Group 2 - For the first half of 2025, the company's operating revenue was 4.790 billion yuan, showing a decline of 7.64% [2][3] - The net profit attributable to the parent company for the first half of 2025 was 386 million yuan, with a decrease of 20.35% [2][3] - The company operates in the healthcare industry, with its main product types including medical auxiliary equipment, accounting for 37.27% of its revenue, and medical trading products at 31.18% [2][3]

Core Viewpoint - Xinhua Medical (600587) has experienced a decline in both revenue and net profit in the first three quarters of 2025, indicating potential challenges in its financial performance [2]. Financial Performance - For the first three quarters of 2025, Xinhua Medical reported a main revenue of 6.978 billion yuan, a year-on-year decrease of 6.0% [2]. - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year [2]. - The net profit after deducting non-recurring items was 370 million yuan, reflecting a significant decline of 38.98% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 2.188 billion yuan, a decrease of 2.2% year-on-year [2]. - The single-quarter net profit attributable to shareholders was approximately 48.59 million yuan, down 63.39% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was about 37.66 million yuan, a decline of 71.77% year-on-year [2]. - The company's debt ratio stands at 45.85%, with investment income of 48.28 million yuan and financial expenses of 21.30 million yuan [2]. - The gross profit margin is reported at 25.11% [2]. Market Activity - As of February 9, 2026, Xinhua Medical's stock closed at 15.5 yuan, with an increase of 0.78% [1]. - The trading volume was 84,400 hands, with a total transaction amount of 131 million yuan [1]. - On February 9, the net outflow of main funds was 13.21 million yuan, accounting for 10.11% of the total transaction amount [1]. - Retail investors contributed a net inflow of 4.02 million yuan, representing 3.08% of the total transaction amount [1]. - Over the past 90 days, one institution has given a rating of "buy" for the stock, with an average target price of 20.0 yuan [3].

| 指标 | 新华医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 93.3亿元 | 110.91亿元 | 43 128 | | 净资产 | 81.64亿元 | 38.15亿元 | 11 128 | | 净利润 | 4.34亿元 | 2.08亿元 | 15 128 | | 市盈率(动) | 16.11 | 91.01 | 4 128 | | 市净率 | 1.18 | ব | 10 128 | | 毛利率 | 25.11% | 50.55% | 113 128 | | 净利率 | 6.36% | 9.59% | 79 128 | | ROE | 5.65% | 0.42% | 48 128 | 证券之星消息，截至2026年2月6日收盘，新华医疗(600587)报收于15.38元，下跌0.45%，换手率 1.51%，成交量9.12万手，成交额1.41亿元。 2月6日的资金流向数据方面，主力资金净流出822.0万元，占总成交额5.82%，游资资金净流入532.41万 元，占总成交额3.77%，散户资金净流入289.59万元，占总成交额2.05%。 近5 ...

Group 1 - The company, Shandong Xinhua Medical Instrument Co., Ltd., has decided to terminate the acquisition of a 36.1913% stake in Wuhan Zhongzhi Biotechnology Co., Ltd. due to the expiration of the delivery deadline as stipulated in the share transfer agreement [2][3]. - The termination was agreed upon after friendly negotiations with all parties involved, including Shenzhen Meijian Electronic Technology Development Co., Ltd. and others, leading to the signing of a supplementary agreement [3]. - The company has not made any payments related to the acquisition, and the termination will not adversely affect its current operating performance or financial status [4]. Group 2 - The company expressed its commitment to continue seeking development opportunities and enhancing its core competitiveness despite the termination of the acquisition [4]. - The company apologized for any inconvenience caused to investors and expressed gratitude for their ongoing support [4].

然而，交易从一开始便伴随估值争议。以2024年5月31日为评估基准日，中帜生物股东权益账面值 8725.52万元，评估值达4.61亿元，增值率高达428.52%，预计产生商誉1.02亿元。这一高溢价引发市场 质疑，在审议该次收购议案时，公司两名董事更投出弃权票，提出"此次收购高估值带来高风险，且无 业绩承诺保证措施做支撑"等原因，直指标的业绩波动与整合不确定性。 从财务数据看，中帜生物的盈利稳定性存在隐忧。2023年，公司实现营业收入1.2亿元、净利润1563.53 万元，但到了2025年上半年则亏损1179.61万元。与此同时，新华医疗自身业绩亦面临压力，2025年前 三季度营收69.78亿元，同比下降6%；归母净利润4.34亿元，同比下降29.61%，公司或在现金流管理与 战略资源分配上更趋审慎。 行业环境的变化进一步加剧了交易的不确定性。2025年，体外诊断行业迎来政策密集调整期：医保支付 方式改革深化，医疗机构控费意愿显著增强；国家药监局发布《关于优化全生命周期监管支持高端医疗 器械创新发展的举措》，支持高端诊断技术产品的研发；六部门联合印发《关于增强消费品供需适配性 进一步促进消费的实施方案》，支持 ...

（编辑 丛可心） 证券日报网讯 2月6日，新华医疗在互动平台回答投资者提问时表示，公司四肢联动康复训练仪在技术 上采用精准联动结构，训练模式丰富、适配性强；价格依托规模化生产具备高性价比；售后覆盖全国服 务网络，响应高效、提供全周期保障。 ...

证券日报网讯2月6日，新华医疗（600587）在互动平台回答投资者提问时表示，直线加速器、大孔径 CT、后装治疗机均为公司放疗核心优势产品，公司将依规参与符合资质的医疗设备招标项目，积极拓 展市场，为公司创造更多价值。 ...

证券日报网讯2月6日，新华医疗（600587）在互动平台回答投资者提问时表示，公司大孔径CT拥有大 孔径、低剂量、精准成像等技术优势，可与放疗设备形成方案协同，性价比与本土化服务优于进口品 牌，目前正依托政策与临床推广加快国产替代。 ...

新华医疗表示，自签订《股份转让协议》以来，公司积极与交易对方就收购事项履行相关审批程序。截 至公告之日，《股份转让协议》约定的交割期限已过，经与交易各方友好协商，决定终止《股份转让协 议》。鉴于本次收购的付款先决条件未达成，公司未支付任何款项，且标的股份非因交易任何一方原因 未能按期交割，公司不存在违约情形。本次收购的终止不会对公司现有经营业绩及财务状况产生不利影 响，不存在损害公司及全体股东利益的情形。公司将努力做好经营管理，不断完善公司发展战略，寻求 更多的发展机会，提升公司核心竞争力，推动公司持续健康发展，争取以更好的业绩回报全体股东。 北京商报讯（记者 丁宁）2月6日晚间，新华医疗（600587）发布公告称，决定终止收购武汉中帜生物 科技股份有限公司（简称"中帜生物"）36.1913%的股权。 ...